Description

Urorek (silodosin) hard capsules 8 mg. №90

Ingredients

Active ingredient: Silodosin 8 mg.
Other ingredients: Lactose monohydrate, pregelatinized starch, hydroxypropyl cellulose, magnesium stearate, gelatin, titanium dioxide, FD&C Blue No. 2.

Dosage

Adults: The recommended dose is 8 mg once daily with a meal. Swallow the capsule whole with water.

Indications

Urorek (silodosin) capsules are indicated for the treatment of benign prostatic hyperplasia (BPH) to improve symptoms such as urinary hesitancy, urgency, and frequency.

Contraindications

Do not use Urorek (silodosin) capsules if you have a known hypersensitivity to silodosin or any of the other ingredients in the product.

Directions

Take Urorek (silodosin) capsules exactly as prescribed by your healthcare provider. Do not exceed the recommended dosage. Consult your doctor for any questions or concerns.

Scientific Evidence

Studies have shown that silodosin, the active ingredient in Urorek capsules, is effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia. Research published in the International Journal of Urology demonstrated that silodosin significantly improved International Prostate Symptom Score (IPSS) and quality of life in patients with BPH.

Additional Information

It is important to note that Urorek (silodosin) capsules may cause dizziness or lightheadedness, especially when standing up from a sitting or lying position. Avoid driving or operating machinery until you know how this medication affects you. Inform your healthcare provider about all the medications you are taking to avoid potential drug interactions.

Pharmacological Effects: Silodosin works by selectively blocking alpha-1 adrenergic receptors in the prostate, bladder base, and urethra. This action leads to relaxation of smooth muscles, improving urine flow and reducing BPH symptoms.

Clinical Trials: Clinical trials have shown that silodosin is well-tolerated and effective in the management of BPH symptoms. A study published in the Journal of Urology found that silodosin was associated with a significant improvement in peak urinary flow rate and reduction in post-void residual volume compared to placebo.